Waldencast plc (WALD)
Consumer Defensive
- Fundamental
- 2
- Sentiment
- 2
- Technical
- 2
Do Nothing: fundamentalScore and qualitativeScore are both 2 (below the required floor of 3), and WALD also fails the strategy's liquidity floors.
Company overview
Waldencast Plc develops and operates a beauty and wellness platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It intends to seek brands with a direct connection to consumers whose goals include pursuing social responsibility, inclusiveness, sustainability, and transparency. The company was founded by Michel Brousset and Hind Sebti on December 8, 2020 and is headquartered in White Plains, NY.
Fundamental
weakWaldencast faces high balance-sheet risk and strategic uncertainty pending the Obagi sale.
Waldencast’s balance sheet appears to have improved sharply after selling the Obagi Medical business (cash-rich, debt eliminated in pro forma disclosures), but the remaining operations still look heavily loss-making. The stock screens very cheap on an enterprise-value-to-sales basis (about 0.13x using continuing-operations revenue), yet that “cheapness” depends on management proving it can shrink losses and stabilize the smaller business.
Sentiment
weakSentiment is mixed with strategic catalysts but also shareholder exits and litigation overhangs.
Near-term coverage is dominated by a reported jump in July short interest (technical, announced) plus a neutral shareholder-approved share repurchase authority, while overall media tone has cooled versus June’s Obagi sale optimism (polarity_score ≈ +0.50 baseline → ≈ -0.10 last ~14d). No regulator-confirmed investigations surfaced in the last 90 days; catalysts skew neutral-to-bearish until a fresh corporate update emerges.
Technical
weakThe short-term trend is constructive but lacks volume for breakout confirmation.
Score 2/5: WALD has a minor oversold rebound off the 1.27-1.30 area and has reclaimed daily VWAP/WMA9, but the stock remains below SMA20/50/200 and EMA9/21 while MACD stays below both its signal and zero; ADX 38 confirms the dominant trend is still bearish.
You’re looking at 2026-08-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Consumer Defensive
Not financial advice. For informational and educational purposes only.